In the News
In the News
Especially given how quickly we are trying to develop a COVID-19 vaccine, it’s a good sign that the AstraZeneca trial paused to investigate an unexplained illness, commented Susan Ellenberg, PhD.
New COVID-19 infections were about 30 percent lower in counties where the highest number of people stopped going in to their offices for work, found research led by Joshua Baker, MD, MSCE.
When we’re offered a COVID-19 vaccine, we should ask: Does it protect people, without causing major toxicities or health problems? If so—and after the FDA and its expert committees review— “I will certainly be in line to get one," Susan Ellenberg, PhD, commented on the radio show Ask an Expert.
For tuberculosis patients who are also HIV-positive, mortality risk is up to four times higher. Gregory Bisson, MD, MSCE, comments on how we can dramatically improve their chances.
In an interview for the American College of Surgeons, Jeffrey Morris, PhD, commented on the tricky timing of pandemic research and on the broad range of issues he has covered in more than 140 Covid Data Science blog posts.
For a useful COVID-19 analogy, look to the time before antilock brakes, says Michael Levy, PhD. “You had to slam on the brakes, ease up a little and apply the brakes again—anand eventually the car would stop.”
Changing behavior now, while the COVID19 increase is still manageable, is the best way for Colorado to avoid what’s happening in Houston, where ICUs have been overwhelmed, commented Jeffrey Morris, PhD.
Some challenges that confront scientists racing to develop COVID-19 treatments and vaccines resemble those faced in the past—with HIV, SARS, H1N1 and Ebola—while others are new. Susan Ellenberg, PhD, unpacks what we need to know about clinical trials during the current pandemic. Read the perspective piece in Clinical Trials.
Seeing groups hanging out together at concerts, bars and parties with few masks in sight, “It’s not surprising that people are spreading the virus,” Ebbing Lautenbach, MD, MPH, MSCE, told Philadelphia’s NBC10.
Declining COVID19 mortality rates shouldn’t be used to minimize the risk of the current surges, says Jeffrey Morris, PhD. He added, “Different parts of the country are experiencing very different things. It is kind of a paradox.”
To understand health and disease today, we need new thinking and novel science —the kind we create when multiple disciplines work together from the ground up. That is why this department has put forward a bold vision in population-health science: a single academic home for biostatistics, epidemiology and informatics.